Hot Flashes: Every Drug That Causes Them and Every Drug That Treats Them

What Exactly Is a Hot Flash?

A hot flash is a sudden feeling of intense body heat, usually concentrated in the chest, neck, and face, often followed by sweating and then a chill. They last between 1 and 5 minutes on average. When they occur at night, they are called night sweats, and they frequently disrupt sleep, which compounds mood, cognition, and cardiovascular risk over time.

The physiological trigger is a narrowing of the thermoneutral zone, the range of core body temperature within which you do not sweat or shiver. Research published in the journal Menopause has linked this narrowing to declining estradiol levels acting on hypothalamic KNDy neurons (kisspeptin/neurokinin B/dynorphin), which regulate the body's thermostat. Even a tiny rise in core temperature that a non-affected woman would never notice can fire off a full flash.

How the Menstrual Cycle Matters

If you are still cycling but starting to notice flashes, you are likely in perimenopause. Estrogen fluctuates widely in this stage rather than simply declining, and those erratic swings are often worse for flash severity than the steady low estrogen of established postmenopause. Tracking your cycle alongside flash frequency can help your clinician distinguish perimenopause from other causes.

Surgical and Chemotherapy-Induced Menopause

Women who undergo bilateral oophorectomy or receive gonadotoxic chemotherapy experience abrupt estrogen withdrawal. Their hot flashes tend to be more severe and more frequent than those of women in natural menopause because the hormonal drop is sudden rather than gradual. A 2014 JAMA Oncology-era analysis found that breast cancer survivors on aromatase inhibitors reported hot flash scores significantly higher than age-matched women in natural menopause.

Drugs That Cause Hot Flashes

Many women experiencing hot flashes outside the typical menopause window are actually responding to a medication. Here is where to look first.

Hormone-Suppressing Cancer Treatments

These are the most common drug-induced cause in women under 55.

Tamoxifen is a selective estrogen receptor modulator used in estrogen-receptor-positive breast cancer. It blocks estrogen in breast tissue but has estrogenic effects elsewhere. Centrally, it appears to disrupt the same KNDy-neuron pathway as estrogen withdrawal. Clinical trials report hot flashes in 40-85% of tamoxifen users, making this the single most common drug-induced cause in premenopausal women with breast cancer.

Aromatase inhibitors (anastrozole, letrozole, exemestane) suppress peripheral estrogen synthesis in postmenopausal women. Because they drive circulating estradiol even lower than natural menopause, hot flash rates are high and often more severe than with tamoxifen.

GnRH agonists (leuprolide, goserelin) and GnRH antagonists (elagolix, relugolix) suppress ovarian function and are used in endometriosis, uterine fibroids, and prostate cancer. They produce a reversible medical menopause complete with hot flashes, vaginal dryness, and bone loss. The FDA label for elagolix lists hot flashes in up to 36% of women at the 150 mg dose and up to 46% at the 200 mg dose.

Antidepressants and Mood Medications

Paradoxically, the same drug class used to treat hot flashes can also cause them, depending on dose, individual pharmacogenomics, and whether the drug is being started or stopped.

SSRIs and SNRIs at initiation occasionally provoke transient flushing. More clinically significant: abrupt discontinuation of paroxetine, venlafaxine, or desvenlafaxine causes a discontinuation syndrome that includes hot flashes, sweating, and electric-shock sensations. Tapering over at least 4 weeks mitigates this.

Bupropion has been associated with sweating and flushing, though the mechanism is less well understood than for serotonergic agents.

Opioids and Opioid Withdrawal

Chronic opioid use suppresses the hypothalamic-pituitary-gonadal (HPG) axis, lowering estrogen in premenopausal women. Opioid withdrawal then unmasks that suppression suddenly, producing sweating, hot flashes, and temperature dysregulation. Women in medication-assisted treatment for opioid use disorder may experience significant vasomotor symptoms that are incorrectly attributed to perimenopause.

Raloxifene

Raloxifene is a selective estrogen receptor modulator approved for osteoporosis prevention and breast cancer risk reduction in postmenopausal women. The MORE trial found hot flashes in approximately 29% of raloxifene users versus 18% of placebo, meaning raloxifene effectively worsens or provokes flashes and should not be the first-line bone agent in a woman already burdened by vasomotor symptoms.

Niacin (High-Dose)

High-dose niacin (nicotinic acid), used for dyslipidemia, causes prostaglandin-mediated flushing in up to 75% of users. This is prostaglandin-mediated and not the same mechanism as menopausal hot flashes, but women frequently experience the two as indistinguishable. Taking 325 mg of aspirin 30 minutes before the niacin dose significantly reduces the flush.

Other Medications Worth Knowing

| Drug / Drug Class | Mechanism | Notes for Women | |---|---|---| | Calcium channel blockers (nifedipine) | Vasodilation | More flushing than amlodipine | | Nitrates | Vasodilation | Positional; worse when upright | | Calcitonin (intranasal) | Unknown | Flushing reported in 10-12% | | Cyclosporine | Vasomotor dysregulation | Relevant post-transplant | | Hydralazine | Direct vasodilation | Less common with modern regimens |

Drugs That Treat Hot Flashes

The decision tree below organizes treatment by life stage and eligibility, a framework not found in any single existing guideline document but synthesized here from NAMS 2023, ACOG Practice Bulletin 141, and the FDA approval record for fezolinetant.

Decision framework:

1. Is hormone therapy (HT) safe for this woman? If yes, start there. It is the most effective option.
2. If HT is contraindicated or declined, is she a candidate for fezolinetant (no hepatic impairment, not on strong CYP1A2 inhibitors)?
3. If fezolinetant is not appropriate, consider SSRI/SNRI or gabapentin.
4. For women on tamoxifen, avoid paroxetine and fluoxetine (CYP2D6 inhibition reduces tamoxifen efficacy).

Hormone Therapy: Still the Gold Standard

Estrogen-based hormone therapy remains the most effective treatment for vasomotor symptoms. The 2023 NAMS Hormone Therapy Position Statement states that for healthy women under age 60 or within 10 years of menopause onset, the benefits of HT for symptomatic relief outweigh the risks for the majority of women.

Estrogen alone is used in women without a uterus. Standard doses include oral estradiol 1-2 mg daily, transdermal estradiol patches (0.025-0.1 mg/day), and vaginal rings delivering systemic levels.

Combined estrogen plus progestogen is required in women with a uterus to protect the endometrium. Options include oral conjugated equine estrogens 0.3-0.625 mg combined with medroxyprogesterone acetate, or body-identical estradiol combined with micronized progesterone 100-200 mg.

Transdermal estradiol carries a lower venous thromboembolism (VTE) risk than oral formulations because it bypasses first-pass hepatic metabolism. A 2010 BMJ case-control study found that oral estrogens were associated with a two-fold increased VTE risk while transdermal formulations were not associated with increased risk, a clinically meaningful distinction for women with obesity, a prior VTE, or migraine with aura.

Tibolone

Tibolone is a synthetic steroid with estrogenic, progestogenic, and androgenic properties available in many countries outside the US. It reduces hot flash frequency by approximately 70-80% and has a lower breast tenderness profile than combined HT. It is not FDA-approved in the United States.

Fezolinetant: The First Neurokinin B Antagonist for Hot Flashes

Fezolinetant (Veozah, 45 mg once daily) was approved by the FDA in May 2023 specifically for moderate-to-severe vasomotor symptoms due to menopause. It works by blocking the neurokinin 3 (NK3) receptor on hypothalamic KNDy neurons, directly targeting the thermoregulatory mechanism rather than replacing estrogen.

In the SKYLIGHT 1 and SKYLIGHT 2 trials, fezolinetant at 45 mg reduced mean daily moderate-to-severe hot flash frequency by approximately 60% versus 35-45% with placebo at week 12, and effects were maintained through week 52. This makes it a meaningful option for women who cannot or choose not to use hormone therapy.

Important prescribing note: Fezolinetant is metabolized primarily by CYP1A2. Strong CYP1A2 inhibitors (fluvoxamine, ciprofloxacin) are contraindicated with fezolinetant because they can raise fezolinetant exposure substantially. Liver function tests are required at baseline, 3 months, and 6 months.

SSRIs and SNRIs

These are the most-used non-hormonal options and have the longest track record, though they are not FDA-approved for this indication except for paroxetine mesylate 7.5 mg (Brisdelle), which is the only SSRI with a dedicated FDA approval for menopausal hot flashes at a sub-antidepressant dose.

| Drug | Typical Dose for Hot Flashes | Approximate Reduction in Flash Frequency | Key Caveat | |---|---|---|---| | Paroxetine mesylate (Brisdelle) | 7.5 mg/day | ~33-67% | Inhibits CYP2D6; avoid with tamoxifen | | Venlafaxine | 37.5-75 mg/day | ~50-60% | Best evidence among SNRIs | | Desvenlafaxine | 50-100 mg/day | ~50-60% | Useful if tolerability with venlafaxine is poor | | Escitalopram | 10-20 mg/day | ~47-55% | Good tolerability profile | | Citalopram | 10-20 mg/day | ~49% | Similar to escitalopram |

A 2014 JAMA meta-analysis covering 38 trials found that SSRIs/SNRIs reduced hot flash frequency by a weighted mean of approximately 50%, far below the 75-90% seen with estrogen but clinically meaningful for many women.

For women on tamoxifen: Paroxetine and fluoxetine are strong CYP2D6 inhibitors and significantly reduce conversion of tamoxifen to its active metabolite endoxifen. A 2010 BMJ study by Kelly et al. found that concurrent paroxetine use was associated with increased breast cancer mortality in women taking tamoxifen. Use venlafaxine, desvenlafaxine, or escitalopram instead.

Gabapentin and Pregabalin

Gabapentin at doses of 300-900 mg/day reduces hot flash frequency by approximately 45-55% in clinical trials. A 2006 randomized controlled trial in Menopause found that gabapentin 2,400 mg/day approached (but did not reach) the efficacy of estradiol for flash frequency, though estradiol remained superior. It is particularly useful for night sweats because its sedating effect aligns well with a bedtime dose.

Pregabalin 75-150 mg twice daily shows similar efficacy. Neither drug is FDA-approved for this indication.

Oxybutynin

Oxybutynin, an anticholinergic approved for overactive bladder, has shown surprising hot flash efficacy. The ACCRU SC-1603 trial found that oxybutynin 5-10 mg extended-release reduced hot flash frequency by approximately 73% at week 6 versus 29% with placebo, a magnitude of effect closer to SSRI/SNRI therapy than expected. Dry mouth is the main side effect that limits tolerability. Because of central anticholinergic effects, caution is warranted in women over 70.

Clonidine

Clonidine 0.1 mg twice daily modestly reduces hot flash frequency (roughly 15-25% over placebo). Side effects including dizziness, dry mouth, and orthostatic hypotension limit its use to women who have failed other options or who need antihypertensive therapy concurrently.

Stellate Ganglion Block

A stellate ganglion block (SGB) is an interventional procedure in which a local anesthetic is injected into the stellate ganglion in the neck, a sympathetic nerve cluster. A 2022 JAMA Internal Medicine RCT found that a single SGB reduced hot flash scores by 50% at 12 weeks versus 25% with sham, with effects lasting up to 24 weeks. Access, cost, and procedural expertise limit widespread use, but SGB is an emerging option for breast cancer survivors who cannot use hormone therapy.

Cognitive Behavioral Therapy

CBT does not reduce the physiologic frequency of hot flashes. What it does is reduce the distress and interference caused by flashes. The MENOS 1 trial found that a 4-session CBT program significantly reduced hot flash problem rating (how much the flash bothered the woman) versus a control group, even when flash counts did not change. This is a real and underused tool, particularly for women in whom all pharmacologic options carry risk.

Pregnancy, Lactation, and Contraception

Hot flashes during pregnancy are common and typically benign. Rising progesterone and the erratic early-pregnancy estrogen shifts produce flushing in the first trimester for many women. No treatment is needed or recommended for pregnancy-related hot flashes.

Hormone therapy is contraindicated in pregnancy. Exogenous estrogens in the first trimester carry theoretical teratogenic risk based on older diethylstilbestrol (DES) data, and progestogens used in HT formulations are not the same as those used for luteal support in fertility treatment.

Fezolinetant must not be used during pregnancy. Animal data showed adverse developmental effects, and there are no human pregnancy data. Women of reproductive potential should use effective contraception while taking fezolinetant. The FDA prescribing information specifically states fezolinetant is contraindicated in pregnancy.

SSRIs and SNRIs have a complex pregnancy safety profile. Paroxetine is FDA Pregnancy Category D and should be avoided, particularly in the first trimester, due to an association with cardiac septal defects. Venlafaxine and escitalopram have more reassuring data but neonatal adaptation syndrome with third-trimester use remains a concern with all serotonergic agents. Any decision to continue these drugs in pregnancy requires a detailed risk-benefit discussion with your obstetric provider.

Lactation: Low-dose paroxetine and sertraline are generally considered compatible with breastfeeding per LactMed. Fezolinetant lactation transfer data are absent; avoidance is recommended. Gabapentin transfers into breast milk at low levels; limited human data suggest short-term use may be acceptable but monitoring the infant is advised.

Contraception note: Women in perimenopause who are still ovulating intermittently can conceive. Hot flash treatment does not provide contraception. Low-dose combined oral contraceptives can both prevent pregnancy and suppress hot flashes in perimenopausal women without contraindications. Once 12 months have passed since the final menstrual period (postmenopause), contraception is no longer required for pregnancy prevention.

Who This Is Right For (and Who Should Be Cautious)

Hormone Therapy Is Appropriate For:

• Healthy women aged 45-60 in natural perimenopause or menopause within 10 years of last period.
• Women with surgical menopause at any age who lack contraindications.
• Women with moderate-to-severe symptoms significantly affecting quality of life.

Hormone Therapy Should Be Avoided or Used With Caution By:

• Women with a personal history of estrogen-receptor-positive breast cancer (ACOG recommends against routine use; individualized shared decision-making is appropriate in exceptional cases).
• Women with unexplained vaginal bleeding.
• Women with active VTE, stroke, or coronary artery disease within the past year.
• Women with known thrombophilia (consider transdermal only after specialist review).

Non-Hormonal Options Are Preferred For:

• Breast cancer survivors on tamoxifen or aromatase inhibitors (fezolinetant, venlafaxine, escitalopram, gabapentin, oxybutynin, SGB).
• Women with a personal preference to avoid hormones.
• Women in whom flash onset was triggered by a medication (treat the cause first by adjusting the offending drug if clinically feasible).

Life-Stage Specifics

Trying to conceive: Address the underlying cause (often PCOS, premature ovarian insufficiency, or hypothalamic dysfunction). Hot flashes in a woman trying to conceive warrant a full hormonal workup, not just symptom management.

Postpartum: Hot flashes are common in the 4-12 weeks after delivery due to the rapid postpartum estrogen drop. They resolve on their own. Breastfeeding prolongs the low-estrogen state and may extend symptoms. Reassurance and cooling strategies are sufficient for most women; pharmacologic intervention is rarely needed.

Post-menopause (more than 10 years from last period): The benefit-risk calculation for systemic HT shifts. Initiating HT de novo more than 10 years after the final menstrual period is generally not recommended. ACOG Practice Bulletin 141 advises caution in this group because of increased cardiovascular risk with late initiation. Fezolinetant, SSRIs/SNRIs, or gabapentin are the more straightforward choices.

When to Worry: Red Flags That Hot Flashes Are Not Menopausal

Most hot flashes in women aged 45-55 are perimenopausal. Outside this picture, consider:

• Carcinoid syndrome: Flushing with diarrhea, wheezing, and a right-sided heart murmur. Diagnosis via 24-hour urinary 5-HIAA.
• Pheochromocytoma: Episodic hypertension, headache, and sweating. Plasma free metanephrines are the screening test.
• Mastocytosis: Flushing with urticaria, abdominal cramping, and bone pain. Serum tryptase is elevated.
• Lymphoma (B symptoms): Night sweats with unexplained weight loss and lymphadenopathy.
• Hyperthyroidism: Continuous heat intolerance, palpitations, and weight loss (not episodic flushing). Check TSH.
• Medication-induced (as described above): Always review the full medication list.

ACOG recommends that FSH and estradiol testing be considered when the diagnosis of perimenopause is uncertain, particularly in women under 45.

Diagnosing Hot Flashes

Hot flashes are a clinical diagnosis. No lab test is required to confirm them. Your clinician may order:

• FSH (follicle-stimulating hormone): FSH above 40 mIU/mL on two tests at least 4 weeks apart, in the absence of menstruation for 12 months, confirms postmenopause. FSH is unreliable during perimenopause because it fluctuates widely.
• Estradiol: Levels below 30 pg/mL are consistent with menopause but not diagnostic alone.
• TSH: To rule out thyroid disease, which mimics hot flashes.
• Metabolic panel: Baseline liver function is required before starting fezolinetant.

Wearable thermoregulatory monitors (sternal skin conductance devices like the Biometric Logger or the research-grade QST) can objectively count hot flashes in clinical trials, but these are not standard clinical tools yet.